Modus Therapeutics strengthens its board

Modus Therapeutics, a Karolinska Development (STO:KDEV) portfolio company focused on innovative treatments for patients with sickle-cell disease, announces Jim Van heusden has been elected as a new member of the board.

Jim Van heusden is CEO of Karolinska Development, having joined in March 2015. He has more than 20 years’ experience within venture capital, drug discovery and development within the pharmaceutical industry, including as Founder and Managing Director at bioskills (2013-2015) and as Partner at the European investment company Gimv (2001-2013). During his appointment at Gimv he also served as a Board member in several biotech companies including Multiplicom (as Chairman), Ablynx, ActoGeniX, Pronota and Prosensa. During 1993-2001, he worked as Senior Scientist at Janssen Pharmaceuticals (Johnson & Johnson).

He holds BSc and MSc degrees in chemistry and biochemistry from the University of Antwerp and a PhD in molecular and cellular biology from the University of Maastricht.

“We are pleased to welcome Jim Van heusden to the Modus Therapeutics board, as he brings with him his years of experience in the life science industry, together with unique entrepreneurial skills,” said Modus Therapeutics CEO Christina Herder.